<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TRIESENCE- triamcinolone acetonide injection </strong><br>Alcon Laboratories, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL safely and effectively. See full prescribing information for TRIESENCE® suspension.</span><br><span class="Bold">TRIESENCE® (triamcinolone acetonide injectable suspension)</span><br><span class="Bold">40 mg/mL</span><br><span class="Bold">Initial U.S. Approval: 1957</span>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">TRIESENCE® suspension is a synthetic corticosteroid indicated for:  </p>
<p class="Highlighta">• Treatment of the following ophthalmic diseases: sympathetic ophthalmia, <span class="product-label-link" type="condition" conceptid="4290976" conceptname="Temporal arteritis">temporal arteritis</span>, <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>, and ocular inflammatory conditions unresponsive to topical corticosteroids. (<span class="Underline"><a href="#splSection1">1.1</a></span>) </p>
<p class="Highlighta">• Visualization during vitrectomy. (<span class="Underline"><a href="#splSection2">1.2</a></span>) </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">• Initial recommended dose for all indications except visualization: 4 mg (100 microliters of 40 mg/mL suspension) with subsequent dosage as needed over the course of treatment. (<span class="Underline"><a href="#splSection3">2.1</a></span>) </p>
<p class="Highlighta">• Recommended dose for visualization: 1 to 4 mg (25 to 100 microliters of 40 mg/mL suspension) administered intravitreally. (<span class="Underline"><a href="#splSection4">2.2</a></span>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Single use 1 mL vial containing 40 mg/mL of triamcinolone acetonide suspension. (<span class="Underline"><a href="#splSectionPLRDosageFormsStrength">3</a></span>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<p class="Highlighta">• Patients with systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>. (<span class="Underline"><a href="#splSectionPLRContraindications">4</a></span>) </p>
<p class="Highlighta">• <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to triamcinolone or any component of this product. (<span class="Underline"><a href="#splSectionPLRContraindications">4</a></span>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<p class="Highlighta">• TRIESENCE® suspension should not be administered intravenously. (<span class="Underline"><a href="#splSection7">5.1</a></span>) </p>
<p class="Highlighta">• Ophthalmic effects: May include <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Monitor intraocular pressure. (<span class="Underline"><a href="#splSection7">5.1</a></span>) </p>
<p class="Highlighta">• Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>: Monitor patients for these conditions and taper doses gradually. (<span class="Underline"><a href="#splSection8">5.2</a></span>) </p>
<p class="Highlighta">• <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>: Increased susceptibility to new <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and increased risk of exacerbation, dissemination, or reactivation of latent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. (<span class="Underline"><a href="#splSection9">5.3</a></span>) </p>
<p class="Highlighta">• Elevated blood pressure, salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>, and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>: Monitor blood pressure and sodium, potassium serum levels. (<span class="Underline"><a href="#splSection10">5.4</a></span>) </p>
<p class="Highlighta">• <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">GI perforation</span>: Increased risk in patients with certain GI disorders. (<span class="Underline"><a href="#splSection11">5.5</a></span>) </p>
<p class="Highlighta">• Behavioral and mood disturbances: May include <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. (<span class="Underline"><a href="#splSection12">5.6</a></span>) </p>
<p class="Highlighta">• Decreases in bone density: Monitor bone density in patients receiving long term corticosteroid therapy. (<span class="Underline"><a href="#splSection13">5.7</a></span>) </p>
<p class="Highlighta">• Live or live attenuated vaccines: Do not administer to patients receiving immunosuppressive doses of corticosteroids. (<span class="Underline"><a href="#splSection14">5.8</a></span>) </p>
<p class="Highlighta">• Negative effects on growth and development: Monitor pediatric patients on long-term corticosteroid therapy. (<span class="Underline"><a href="#splSection15">5.9</a></span>) </p>
<p class="Highlighta">• Use in pregnancy: Fetal harm can occur with first trimester use. (<span class="Underline"><a href="#splSection16">5.10</a></span>) </p>
<p class="Highlighta">• <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span>: May cause <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>. (<span class="Underline"><a href="#splSection17">5.11</a></span>) </p>
<p class="Highlighta">        </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Alcon Laboratories, Inc. at 1-800-757-9195 or FDA at 1-800-FDA-1088 or </span><span class="Bold Underline">www.fda.gov/medwatch</span>. </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="Highlighta">• Anticoagulant agents: May enhance or diminish anticoagulant effects. Monitor coagulation indices. (<span class="Underline"><a href="#splSectionPLRDrugInteract">7</a></span>) </p>
<p class="Highlighta">• Antidiabetic agents: May increase blood glucose concentrations. Dose adjustments of antidiabetic agents may be required. (<span class="Underline"><a href="#splSectionPLRDrugInteract">7</a></span>) </p>
<p class="Highlighta">• CYP 3A4 inducers and inhibitors: May respectively increase or decrease clearance of corticosteroids necessitating dose adjustment. (<span class="Underline"><a href="#splSectionPLRDrugInteract">7</a></span>) </p>
<p class="Highlighta">• NSAIDS including aspirin and salicylates: Increased risk of gastrointestinal side effects. (<span class="Underline"><a href="#splSectionPLRDrugInteract">7</a></span>) </p>
</div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 9/2010</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">
1 INDICATIONS AND USAGE
</a></h1>
<h2><a href="#section-1.1" class="toc">
1.1 Ophthalmic Diseases
</a></h2>
<h2><a href="#section-1.2" class="toc">
1.2 Visualization during Vitrectomy
</a></h2>
<h1><a href="#section-2" class="toc">
2 DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc">
2.1 Dosage for Treatment of Ophthalmic Diseases
</a></h2>
<h2><a href="#section-2.2" class="toc">
2.2 Dosage for Visualization during Vitrectomy
</a></h2>
<h2><a href="#section-2.3" class="toc">
2.3 Preparation for Administration
</a></h2>
<h2><a href="#section-2.4" class="toc">
2.4 Administration
</a></h2>
<h1><a href="#section-3" class="toc">
3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">
4 CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">
5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">
5.1 Ophthalmic Effects
</a></h2>
<h2><a href="#section-5.2" class="toc">
5.2 Alterations in Endocrine Function
</a></h2>
<h2><a href="#section-5.3" class="toc">
5.3 Increased Risks Related to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>
</a></h2>
<h2><a href="#section-5.4" class="toc">
5.4 Alterations in Cardiovascular/Renal Function
</a></h2>
<h2><a href="#section-5.5" class="toc">
5.5 Use in Patients with <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>
</a></h2>
<h2><a href="#section-5.6" class="toc">
5.6 Behavioral and Mood Disturbances
</a></h2>
<h2><a href="#section-5.7" class="toc">
5.7 Decrease in Bone Density
</a></h2>
<h2><a href="#section-5.8" class="toc">
5.8 Vaccination
</a></h2>
<h2><a href="#section-5.9" class="toc">
5.9 Effect on Growth and Development
</a></h2>
<h2><a href="#section-5.10" class="toc">
5.10 Use in Pregnancy
</a></h2>
<h2><a href="#section-5.11" class="toc">
5.11 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span>
</a></h2>
<h2><a href="#section-5.12" class="toc">
5.12 Neuromuscular Effects
</a></h2>
<h2><a href="#section-5.13" class="toc">
5.13 Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">Sarcoma</span>
</a></h2>
<h1><a href="#section-6" class="toc">
6 ADVERSE REACTIONS
</a></h1>
<h1><a href="#section-7" class="toc">
7 DRUG INTERACTIONS
</a></h1>
<h1><a href="#section-8" class="toc">
8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">
8.1 Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">
8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-8.3" class="toc">
8.4 Pediatric Use
</a></h2>
<h2><a href="#section-8.4" class="toc">
8.5 Geriatric Use
</a></h2>
<h1><a href="#section-9" class="toc">
11 DESCRIPTION
</a></h1>
<h1><a href="#section-10" class="toc">
12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-10.1" class="toc">
12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-10.2" class="toc">
12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-11" class="toc">
13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h2><a href="#section-11.2" class="toc">
13.2 Animal Toxicology and/or Pharmacology
</a></h2>
<h1><a href="#section-12" class="toc">
16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-13" class="toc">
17 PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="splSectionPLRIndicationsUsage"></a><a name="section-1"></a><p></p>
<h1>
1 INDICATIONS AND USAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection1"></a><a name="section-1.1"></a><p></p>
<h2>
1.1 Ophthalmic Diseases
</h2>
<p class="First">TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL is indicated for:</p>
<p>• sympathetic ophthalmia,</p>
<p>• <span class="product-label-link" type="condition" conceptid="4290976" conceptname="Temporal arteritis">temporal arteritis</span>,</p>
<p>• <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>, and</p>
<p>• ocular inflammatory conditions unresponsive to topical corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection2"></a><a name="section-1.2"></a><p></p>
<h2>
1.2 Visualization during Vitrectomy
</h2>
<p class="First">TRIESENCE® suspension is indicated for visualization during vitrectomy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="splSectionPLRDosageAdministration"></a><a name="section-2"></a><p></p>
<h1>
2 DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection3"></a><a name="section-2.1"></a><p></p>
<h2>
2.1 Dosage for Treatment of Ophthalmic Diseases
</h2>
<p class="First">The initial recommended dose of TRIESENCE® suspension is 4 mg (100 microliters of 40 mg/mL suspension) with subsequent dosage as needed over the course of treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection4"></a><a name="section-2.2"></a><p></p>
<h2>
2.2 Dosage for Visualization during Vitrectomy
</h2>
<p class="First">The recommended dose of TRIESENCE® suspension is 1 to 4 mg (25 to 100 microliters of 40 mg/mL suspension) administered intravitreally.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection5"></a><a name="section-2.3"></a><p></p>
<h2>
2.3 Preparation for Administration
</h2>
<p class="First"><span class="Bold">STRICT ASEPTIC TECHNIQUE IS MANDATORY. </span>The vial should be vigorously shaken for 10 seconds before use to ensure a uniform suspension. Prior to withdrawal, the suspension should be inspected for clumping or granular appearance (agglomeration). An agglomerated product results from exposure to freezing temperatures and should not be used. After withdrawal, TRIESENCE® suspension should be injected without delay to prevent settling in the syringe. Careful technique should be employed to avoid the possibility of entering a blood vessel or introducing organisms that can cause <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection6"></a><a name="section-2.4"></a><p></p>
<h2>
2.4 Administration
</h2>
<p class="First">The injection procedure should be carried out under controlled aseptic conditions, which include the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide should be given prior to the injection. Following the injection, patients should be monitored for elevation in intraocular pressure and for <span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">endophthalmitis</span>. Monitoring may consist of a check for perfusion of the optic nerve head immediately after the injection, tonometry within 30 minutes following the injection, and biomicroscopy between two and seven days following the injection. Patients should be instructed to report any symptoms suggestive of <span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">endophthalmitis</span> without delay.</p>
<p>Each vial should only be used for the treatment of a single eye. If the contralateral eye requires treatment, a new vial should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, and injection needles should be changed before TRIESENCE® suspension is administered to the other eye.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="splSectionPLRDosageFormsStrength"></a><a name="section-3"></a><p></p>
<h1>
3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">Single use 1 mL vial containing 40 mg/mL of sterile triamcinolone acetonide suspension.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="splSectionPLRContraindications"></a><a name="section-4"></a><p></p>
<h1>
4 CONTRAINDICATIONS
</h1>
<p class="First">Corticosteroids are contraindicated in patients with systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>.</p>
<p>Triamcinolone is contraindicated in patients who are hypersensitive to corticosteroids or any components of this product. Rare instances of <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have occurred in patients receiving corticosteroid therapy. [<span class="Underline"><a href="#splSectionPLRAdverseReactions">See Adverse Reactions (6)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="splSectionPLRWarnings"></a><a name="section-5"></a><p></p>
<h1>
5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection7"></a><a name="section-5.1"></a><p></p>
<h2>
5.1 Ophthalmic Effects
</h2>
<p class="First">TRIESENCE® suspension should not be administered intravenously. Strict aseptic technique is mandatory.</p>
<p><span class="Italics">Risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></span></p>
<p>Corticosteroids may mask some signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and new <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may appear during their use. There may be decreased resistance and inability to localize <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> when corticosteroids are used. Corticosteroids may enhance the establishment of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to fungi or viruses. If an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> occurs during corticosteroid therapy, it should be promptly controlled by suitable antimicrobial therapy.</p>
<p>See also <span class="Underline"><a href="#splSection9">Increased Risks Related to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> (5.3)</a></span>.</p>
<p><span class="Italics">Elevated Intraocular Pressure</span></p>
<p>Increases in intraocular pressure associated with triamcinolone acetonide injection have been observed in 20-60% of patients. This may lead to <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with possible damage to the optic nerve. Effects on intraocular pressure may last up to 6 months following injection and are usually managed by topical <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> therapy. A small percentage of patients may require aggressive non-topical treatment. Intraocular pressure as well as perfusion of the optic nerve head should be monitored and managed appropriately.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">Endophthalmitis</span></span></p>
<p>The rate of infectious culture positive <span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">endophthalmitis</span> is 0.5%. Proper aseptic techniques should always be used when administering triamcinolone acetonide. In addition, patients should be monitored following the injection to permit early treatment should an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> occur.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataracts</span></span></p>
<p>Use of corticosteroids may produce <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>, particularly <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>.</p>
<p><span class="Italics">Patients with Ocular Herpes Simplex</span></p>
<p>Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">corneal perforation</span>. Corticosteroids <span class="Bold Underline">should not be used in active</span> ocular herpes simplex.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection8"></a><a name="section-5.2"></a><p></p>
<h2>
5.2 Alterations in Endocrine Function
</h2>
<p class="First">Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>. Monitor patients for these conditions with chronic use.</p>
<p>Corticosteroids can produce reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Drug induced <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted.</p>
<p>Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients. Changes in thyroid status of the patient may necessitate adjustment in dosage.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection9"></a><a name="section-5.3"></a><p></p>
<h2>
5.3 Increased Risks Related to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>
</h2>
<p class="First">Corticosteroids may increase the risks related to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> with any pathogen, including viral, bacterial, fungal, protozoan, or <span class="product-label-link" type="condition" conceptid="194873" conceptname="Mixed intestinal helminthiasis">helminthic infections</span>. The degree to which the dose, route and duration of corticosteroid administration correlates with the specific risks of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is not well characterized; however, with increasing doses of corticosteroids, the rate of occurrence of infectious complications increases.</p>
<p>Corticosteroids may mask some signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and may reduce resistance to new <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p>Corticosteroids may exacerbate <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and increase risk of disseminated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. The use of corticosteroids in active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> should be restricted to those cases of fulminating or <span class="product-label-link" type="condition" conceptid="4112387" conceptname="Disseminated tuberculosis">disseminated tuberculosis</span> in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen.</p>
<p><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span> and <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span> can have a more serious or even fatal course in non-immune children or adults on corticosteroids. In children or adults who have not had these diseases, particular care should be taken to avoid exposure. If a patient is exposed to <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>, prophylaxis with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> immune globulin (VZIG) may be indicated. If patient is exposed to <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. If <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> develops, treatment with antiviral agents may be considered.</p>
<p>Corticosteroids should be used with great care in patients with known or suspected Strongyloides (threadworm) <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestation</span>. In such patients, corticosteroid-induced <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span> and potentially fatal gram-negative <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>.</p>
<p>Corticosteroids may increase risk of reactivation or exacerbation of latent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. If corticosteroids are indicated in patients with latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.</p>
<p>Corticosteroids may activate latent <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span>. Therefore, it is recommended that latent or active <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> be ruled out before initiating corticosteroid therapy in any patient who has spent time in the tropics or in any patient with unexplained <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p>Corticosteroids should not be used in <span class="product-label-link" type="condition" conceptid="4202367" conceptname="Cerebral malaria">cerebral malaria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection10"></a><a name="section-5.4"></a><p></p>
<h2>
5.4 Alterations in Cardiovascular/Renal Function
</h2>
<p class="First">Corticosteroids can cause elevation of blood pressure, salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>, and increased excretion of potassium and calcium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. These agents should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
<p>Literature reports suggest an association between use of corticosteroids and left ventricular free wall rupture after a recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>; therefore, therapy with corticosteroids should be used with caution in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection11"></a><a name="section-5.5"></a><p></p>
<h2>
5.5 Use in Patients with <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>
</h2>
<p class="First">There is an increased risk of <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> in patients with certain GI disorders. Signs of <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">GI perforation</span>, such as peritoneal irritation, may be masked in patients receiving corticosteroids. </p>
<p>Corticosteroids should be used with caution if there is a probability of impending perforation, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> or other pyogenic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>; <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>; fresh intestinal anastomoses; and active or latent <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection12"></a><a name="section-5.6"></a><p></p>
<h2>
5.6 Behavioral and Mood Disturbances
</h2>
<p class="First">Corticosteroid use may be associated with central nervous system effects ranging from <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, and severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, to frank <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> manifestations. Also, existing <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span> or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> tendencies may be aggravated by corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection13"></a><a name="section-5.7"></a><p></p>
<h2>
5.7 Decrease in Bone Density
</h2>
<p class="First">Corticosteroids decrease bone formation and increase bone resorption both through their effect on calcium regulation (i.e., decreasing absorption and increasing excretion) and inhibition of osteoblast function. This, together with a decrease in the protein matrix of the bone secondary to an increase in protein catabolism, and reduced sex hormone production, may lead to inhibition of bone growth in children and adolescents and the development of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> at any age. Special consideration should be given to patients at increased risk of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> (i.e., postmenopausal women) before initiating corticosteroid therapy and bone density should be monitored in patients on long term corticosteroid therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection14"></a><a name="section-5.8"></a><p></p>
<h2>
5.8 Vaccination
</h2>
<p class="First">Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered; however, the response to such vaccines cannot be predicted. Immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for Addison's disease.</p>
<p>While on corticosteroid therapy, patients should not be vaccinated against <span class="product-label-link" type="condition" conceptid="134573" conceptname="Smallpox">smallpox</span>. Other immunization procedures should not be undertaken in patients who are on corticosteroids, especially on high dose, because of possible hazards of neurological complications and a lack of antibody response.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection15"></a><a name="section-5.9"></a><p></p>
<h2>
5.9 Effect on Growth and Development
</h2>
<p class="First">Long-term use of corticosteroids can have negative effects on growth and development in children. Growth and development of pediatric patients on prolonged corticosteroid therapy should be carefully monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection20"></a><a name="section-5.10"></a><p></p>
<h2>
5.10 Use in Pregnancy
</h2>
<p class="First">Triamcinolone acetonide can cause fetal harm when administered to a pregnant woman. Human and animal studies suggest that use of corticosteroids during the first trimester of pregnancy is associated with an increased risk of orofacial clefts, intrauterine growth restriction and decreased birth weight. If this drug is used during pregnancy, or if the patient becomes pregnant while using this drug, the patient should be apprised of the potential hazard to the fetus. [See <span class="Underline"><a href="#splSectionPLRPregnancy">Use in</a></span><span class="Underline">Specific Populations (8.1)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection17"></a><a name="section-5.11"></a><p></p>
<h2>
5.11 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span>
</h2>
<p class="First">Systemically administered corticosteroids may increase appetite and cause <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection18"></a><a name="section-5.12"></a><p></p>
<h2>
5.12 Neuromuscular Effects
</h2>
<p class="First">Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>, they do not show that they affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect.</p>
<p>An <span class="product-label-link" type="condition" conceptid="4102023" conceptname="Proximal myopathy">acute myopathy</span> has been observed with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (e.g., <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>), or in patients receiving concomitant therapy with neuromuscular blocking drugs (e.g., pancuronium). This <span class="product-label-link" type="condition" conceptid="4102023" conceptname="Proximal myopathy">acute myopathy</span> is generalized, may involve ocular and respiratory muscles, and may result in <span class="product-label-link" type="condition" conceptid="444419" conceptname="Tetraparesis">quadriparesis</span>. Elevation of creatine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection19"></a><a name="section-5.13"></a><p></p>
<h2>
5.13 Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">Sarcoma</span>
</h2>
<p class="First">Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span> has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="splSectionPLRAdverseReactions"></a><a name="section-6"></a><p></p>
<h1>
6 ADVERSE REACTIONS
</h1>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>Adverse event data were collected from 300 published articles containing data from controlled and uncontrolled clinical trials which evaluated over 14,000 eyes treated with different concentrations of triamcinolone acetonide. The most common dose administered within these trials was triamcinolone acetonide 4 mg administered as primary or adjunctive therapy primarily as a single injection.</p>
<p>The most common reported adverse events following administration of triamcinolone acetonide were elevated intraocular pressure and <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> progression. These events have been reported to occur in 20-60% of patients.</p>
<p>Less common reactions occurring in up to 2% include <span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">endophthalmitis</span> (infectious and non-infectious), <span class="product-label-link" type="condition" conceptid="439018" conceptname="Hypopyon">hypopyon</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span> (described as blurring and transient <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>), <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="4034681" conceptname="Vitreous floaters">vitreous floaters</span>, and <span class="product-label-link" type="condition" conceptid="441851" conceptname="Serous detachment of retinal pigment epithelium">detachment of retinal pigment epithelium</span>, optic disc <span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">vascular disorder</span>, <span class="product-label-link" type="condition" conceptid="376709" conceptname="Discharge of eye">eye inflammation</span>, <span class="product-label-link" type="condition" conceptid="378756" conceptname="Conjunctival hemorrhage">conjunctival hemorrhage</span> and <span class="product-label-link" type="condition" conceptid="376402" conceptname="Low vision, one eye">visual acuity reduced</span>. Cases of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">exophthalmos</span> have also been reported.</p>
<p>Common adverse reactions for systemically administered corticosteroids include <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, alteration in glucose tolerance, elevation in blood pressure, behavioral and <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span> and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.</p>
<p>Other reactions reported to have occurred with the administration of corticosteroids include:</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span>: </span><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reaction</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span></p>
<p><span class="Bold">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, cardiac enlargement, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4057039" conceptname="Fat embolism">fat embolism</span>, <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span> in premature infants, <span class="product-label-link" type="condition" conceptid="4107225" conceptname="Rupture of heart">myocardial rupture</span> following recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span></p>
<p><span class="Bold">Dermatologic: </span><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>, <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">allergic dermatitis</span>, cutaneous and subcutaneous <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry scalp</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, facial <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, hyper or hypopigmentation, impaired <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span> and <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, sterile <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, suppressed reactions to skin tests, thin fragile skin, thinning scalp hair, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p><span class="Bold">Endocrine: </span>Abnormal fat deposits, decreased carbohydrate tolerance, development of <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">Cushingoid</span> state, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, manifestations of <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span> mellitus and increased requirements for insulin or oral hypoglycemic agents in diabetics, menstrual irregularities, moon facies, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery or illness), suppression of growth in children</p>
<p><span class="Bold">Fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Disturbances</span>: </span>Potassium loss, <span class="product-label-link" type="condition" conceptid="4332017" conceptname="Hypokalemic alkalosis">hypokalemic alkalosis</span>, <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span> </p>
<p><span class="Bold">Gastrointestinal: </span>Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, elevation in serum liver enzymes levels (usually reversible upon discontinuation), <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccups</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span> with possible perforation and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, ulcerative <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span></p>
<p><span class="Bold">Metabolic: </span>Negative nitrogen balance due to protein catabolism</p>
<p><span class="Bold">Musculoskeletal: </span><span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Aseptic necrosis</span> of femoral and humeral heads, charcot-like <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span>, loss of <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> of long bones, <span class="product-label-link" type="condition" conceptid="4097390" conceptname="Steroid-induced myopathy">steroid myopathy</span>, <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span>, vertebral <span class="product-label-link" type="condition" conceptid="4071579" conceptname="Compression fracture">compression fractures</span></p>
<p><span class="Bold">Neurological: </span><span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">Arachnoiditis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> with <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> (pseudo-tumor cerebri) usually following discontinuation of treatment, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4081615" conceptname="Paraparesis">paraparesis</span>/<span class="product-label-link" type="condition" conceptid="192606" conceptname="Paraplegia">paraplegia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4311114" conceptname="Sensory disorder">sensory disturbances</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Bold">Reproductive: </span>Alteration in motility and number of spermatozoa.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="splSectionPLRDrugInteract"></a><a name="section-7"></a><p></p>
<h1>
7 DRUG INTERACTIONS
</h1>
<p class="First">• <span class="Bold">Amphotericin B: </span>There have been cases reported in which concomitant use of Amphotericin B and hydrocortisone was followed by cardiac enlargement and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. <span class="Italics">See Potassium depleting agents.</span></p>
<p>• <span class="Bold">Anticholinesterase agents: </span>Concomitant use of anticholinesterase agents and corticosteroids may produce severe <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.</p>
<p>• <span class="Bold">Anticoagulant agents: </span>Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect.</p>
<p>• <span class="Bold">Antidiabetic agents: </span>Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.</p>
<p>• <span class="Bold">Antitubercular drugs: </span>Serum concentrations of isoniazid may be decreased.</p>
<p>• <span class="Bold">CYP 3A4 inducers (e.g., barbiturates, phenytoin, carbamazepine, and rifampin): </span>Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of corticosteroid and require that the dosage of corticosteroid be increased.</p>
<p>• <span class="Bold">CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): </span>Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects.</p>
<p>• <span class="Bold">Cholestyramine: </span>Cholestyramine may increase the clearance of corticosteroids.</p>
<p>• <span class="Bold">Cyclosporine: </span><span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Increased activity</span> of both cyclosporine and corticosteroids may occur when the two are used concurrently. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> have been reported with concurrent use.</p>
<p>• <span class="Bold">Digitalis: </span>Patients on digitalis glycosides may be at increased risk of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> due to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
<p>• <span class="Bold">Estrogens, including oral contraceptives: </span>Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect.</p>
<p>• <span class="Bold">NSAIDS including aspirin and salicylates: </span>Concomitant use of aspirin or other non-steroidal antiinflammatory agents and corticosteroids increases the risk of gastrointestinal side effects.  Aspirin should be used cautiously in conjunction with corticosteroids in <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>. The clearance of salicylates may be increased with concurrent use of corticosteroids.</p>
<p>• <span class="Bold">Potassium depleting agents (e.g., diuretics, Amphotericin B): </span>When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
<p>• <span class="Bold">Skin tests: </span>Corticosteroids may suppress reactions to skin tests.</p>
<p>• <span class="Bold">Toxoids and live or inactivated vaccines: </span>Due to inhibition of antibody response, patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="splSectionPLRPopulations"></a><a name="section-8"></a><p></p>
<h1>
8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="splSectionPLRPregnancy"></a><a name="section-8.1"></a><p></p>
<h2>
8.1 Pregnancy
</h2>
<p class="First"><span class="Bold">Teratogenic Effects: Pregnancy Category D </span></p>
<p>[See <span class="Underline"><a href="#splSection16">Warnings and Precautions (5.10)</a></span>]</p>
<p>Multiple cohort and case controlled studies in humans suggest that maternal corticosteroid use during the first trimester increases the rate of <span class="product-label-link" type="condition" conceptid="133861" conceptname="Cleft lip">cleft lip</span> with or without <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> from about 1/1000 infants to 3- 5/1000 infants. Two prospective case control studies showed decreased birth weight in infants exposed to maternal corticosteroids in utero.</p>
<p>Triamcinolone acetonide was teratogenic in rats, rabbits, and monkeys. In rats and rabbits, triamcinolone acetonide was teratogenic at inhalation doses of 0.02 mg/kg and above and in monkeys, triamcinolone acetonide was teratogenic at an inhalation dose of 0.5 mg/kg (1/4 and 7 times the recommended human dose). Dose-related teratogenic effects in rats and rabbits included <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> and/or internal <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephaly</span> and axial skeletal defects, whereas the effects observed in monkeys were cranial malformations. These effects are similar to those noted with other corticosteroids.</p>
<p>Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who received corticosteroids during pregnancy should be carefully observed for signs of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="splSectionPLRNursing"></a><a name="section-8.2"></a><p></p>
<h2>
8.3 Nursing Mothers
</h2>
<p class="First">Corticosteroids are secreted in human milk. Reports suggest that steroid concentrations in human milk are 5 to 25% of maternal serum levels, and that total infant daily doses are small, less than 0.2% of the maternal daily dose. The risk of infant exposure to steroids through breast milk should be weighed against the known benefits of breastfeeding for both the mother and baby.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="splSectionPLRPediatric"></a><a name="section-8.3"></a><p></p>
<h2>
8.4 Pediatric Use
</h2>
<p class="First">The efficacy and safety of corticosteroids in the pediatric population are based on the well established course of effect of corticosteroids which is similar in pediatric and adult populations.</p>
<p>The adverse effects of corticosteroids in pediatric patients are similar to those in adults. [See <span class="Underline"><a href="#splSectionPLRAdverseReactions">Adverse Reactions (6)</a></span>].</p>
<p>Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, intraocular pressure, and clinical evaluation for the presence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, psychosocial disturbances, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcers</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>, and <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. Children, who are treated with corticosteroids by any route, including systemically administered corticosteroids, may experience a decrease in their growth velocity. This negative impact of corticosteroids on growth has been observed at low systemic doses and in the absence of laboratory evidence of HPA axis suppression (i.e., cosyntropin stimulation and basal cortisol plasma levels). Growth velocity may therefore be a more sensitive indicator of systemic corticosteroid exposure in children than some commonly used tests of HPA axis function. The linear growth of children treated with corticosteroids by any route should be monitored, and the potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of other treatment alternatives. In order to minimize the potential growth effects of corticosteroids, children should be titrated to the lowest effective dose.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="splSectionPLRGeriatric"></a><a name="section-8.4"></a><p></p>
<h2>
8.5 Geriatric Use
</h2>
<p class="First">No overall differences in safety or effectiveness were observed between elderly subjects and younger subjects, and other reported clinical experience with triamcinolone has not identified differences in responses between the elderly and younger patients. However, the incidence of corticosteroid-induced side effects may be increased in geriatric patients and are dose-related. <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span> is the most frequently encountered complication, which occurs at a higher incidence rate in corticosteroid-treated geriatric patients as compared to younger populations and in age-matched controls. Losses of bone mineral density appear to be greatest early on in the course of treatment and may recover over time after steroid withdrawal or use of lower doses.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="splSectionPLRDescription"></a><a name="section-9"></a><p></p>
<h1>
11 DESCRIPTION
</h1>
<p class="First">TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL is a synthetic corticosteroid with anti-inflammatory action. Each mL of the sterile, aqueous suspension provides 40 mg of triamcinolone acetonide, with sodium chloride for isotonicity, 0.5% (w/v) carboxymethylcellulose sodium and 0.015% polysorbate 80. It also contains potassium chloride, calcium chloride (dihydrate), magnesium chloride (hexahydrate), sodium acetate (trihydrate), sodium citrate (dihydrate) and water for injection. Sodium hydroxide and hydrochloric acid may be present to adjust pH to a target value 6 - 7.5.</p>
<p>The chemical name for triamcinolone acetonide is 9-Fluro- 11β, 16α, 17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17- acetal with acetone. Its structural formula of C<span class="Sub">24</span>H<span class="Sub">31</span>FO<span class="Sub">6</span> is:</p>
<div class="Figure"><img alt="
chemical
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3f045347-3e5e-4bbd-90f8-6c3100985ca5&amp;name=chemical.jpg"></div>
<p>434.50 MW</p>
<p>Triamcinolone acetonide occurs as a white to cream-colored, crystalline powder having not more than a slight odor and is practically insoluble in water and very soluble in alcohol.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="splSectionPLRClinicalPharm"></a><a name="section-10"></a><p></p>
<h1>
12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="splSectionPLRMechAction"></a><a name="section-10.1"></a><p></p>
<h2>
12.1 Mechanism of Action
</h2>
<p class="First">Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs such as prednisolone and triamcinolone are primarily used for their anti-inflammatory effects in disorders of many organ systems. </p>
<p>Triamcinolone acetonide possesses glucocorticoid activity typical of this class of drug, but with little or no mineralocorticoid activity. For the purposes of comparison, the following is the equivalent milligram dosage of the various glucocorticoids:</p>
<table width="80%">
<col align="left" width="33%">
<col align="center" width="33%">
<col align="center" width="33%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule" align="center">
Cortisone, 25
</th>
<th class="Botrule Lrule Rrule" align="center">
Prednisone, 5
</th>
<th class="Botrule Lrule Rrule" align="center">
Paramethasone, 2
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left">
Hydrocortisone, 20
</td>
<td class="Botrule Lrule Rrule" align="center">
Methylprednisolone, 4
</td>
<td class="Botrule Lrule Rrule" align="center">
Betamethasone, 0.75
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">
Prednisolone, 5
</td>
<td class="Botrule Lrule Rrule" align="center">
Triamcinolone, 4
</td>
<td class="Botrule Lrule Rrule" align="center">
Dexamethasone, 0.75
</td>
</tr>
</tbody>
</table>
<p>Corticosteroids have been demonstrated to depress the production of eosinophils and <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, but erythropoiesis and production of polymorphonuclear leukocytes are stimulated. Inflammatory processes (<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, fibrin deposition, capillary dilatation, migration of leukocytes and phagocytosis) and the later stages of <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing (capillary proliferation, deposition of collagen, cicatrization) are inhibited.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="splSectionPLRPharmacokinetics"></a><a name="section-10.2"></a><p></p>
<h2>
12.3 Pharmacokinetics
</h2>
<p class="First">Aqueous humor pharmacokinetics of triamcinolone have been assessed in 5 patients following a single intravitreal administration (4 mg) of triamcinolone acetonide. Aqueous humor samples were obtained from 5 patients (5 eyes) via an anterior chamber paracentesis on Days 1, 3, 10, 17 and 31 post injection. Peak aqueous humor concentrations of triamcinolone ranged from 2151 to 7202 ng/mL, half-life 76 to 635 hours, and the area under the concentration-time curve (AUC0-t) from 231 to 1911 ng.h/mL following the single intravitreal administration. The mean elimination half-life was 18.7 ± 5.7 days in 4 nonvitrectomized eyes (4 patients). In a patient who had undergone vitrectomy (1 eye), the elimination half-life of triamcinolone from the vitreous was much faster (3.2 days) relative to patients that had not undergone vitrectomy.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="splSectionPLRNonClinical"></a><a name="section-11"></a><p></p>
<h1>
13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="splSectionPLRPrecautionsCarcinogen"></a><a name="section-11.1"></a><p></p>
<h2>
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">No evidence of mutagenicity was detected from in-vitro tests conducted with triamcinolone acetonide including a reverse mutation test in <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> bacteria and a forward mutation test in Chinese hamster ovary cells. With regard to carcinogenicity, in a two-year study in rats, triamcinolone acetonide caused no treatment-related carcinogenicity at oral doses up to 0.001mg/kg and in a two-year study in mice, triamcinolone acetonide caused no treatment-related carcinogenicity at oral doses up to 0.003 mg/kg (less than 1/25th of the recommended human dose). In male and female rats, triamcinolone acetonide caused no change in pregnancy rate at oral doses up to 0.015 mg/kg, but caused increased fetal resorptions and <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> and decreases in pup weight and survival at doses of 0.005 mg/kg (less than 1/10th of the recommended human dose).</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="splSectionPLRAnimalPharm"></a><a name="section-11.2"></a><p></p>
<h2>
13.2 Animal Toxicology and/or Pharmacology
</h2>
<p class="First">Studies were conducted with triamcinolone acetonide, including those employing the proposed dosage form, i.e., 4.0% triamcinolone acetonide injectable suspension formulation containing 0.5% carboxymethylcellulose and 0.015% polysorbate-80 in a balanced salt solution.</p>
<p>Triamcinolone acetonide was demonstrated to be non-inflammatory when injected intravitreally in NZW rabbits, non-cytotoxic to mouse L-929 cells in an in-vitro assay and non-sensitizing in a guinea-pig maximization assay. Furthermore, the results of single-dose intravitreal injection studies with triamcinolone acetonide in both rabbits and monkeys demonstrate that the drug is well tolerated for up to one month with only minor findings of slight decrease in body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and slight <span class="product-label-link" type="condition" conceptid="4307537" conceptname="Corneal thinning">corneal thinning</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="splSectionPLRHowSupplied"></a><a name="section-12"></a><p></p>
<h1>
16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL is supplied as 1 mL of a 40 mg/mL sterile triamcinolone acetonide suspension in a flint Type 1 single use glass vial with a gray rubber stopper and an open target aluminum seal. Each labeled vial is sealed in a polycarbonate <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> with a backing material which provides tamper evidence and is stored in a carton.</p>
<p>• 1 mL single use vial (NDC 0065-0543-01)</p>
<p><span class="Bold">Storage</span></p>
<p>Store at 4° - 25° C (39° - 77° F); Do Not Freeze. Protect from light by storing in carton.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="splSectionPLRPatientInfo"></a><a name="section-13"></a><p></p>
<h1>
17 PATIENT COUNSELING INFORMATION
</h1>
<p class="First">Patients should discuss with their physician if they have had recent or ongoing <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or if they have recently received a vaccine. </p>
<p>There are a number of medicines that can interact with corticosteroids such as triamcinolone. Patients should inform their health-care provider of all the medicines they are taking, including over-thecounter and prescription medicines (such as phenytoin, diuretics, digitalis or digoxin, rifampin, amphotericin B, cyclosporine, insulin or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines, ketoconazole, estrogens including birth control pills and hormone replacement therapy, blood thinners such as warfarin, aspirin or other NSAIDS, barbiturates), dietary supplements, and herbal products. If patients are taking any of these drugs, alternate therapy, dosage adjustment, and/or special test may be needed during the treatment.</p>
<p>Patients should be advised of common adverse reactions that could occur with corticosteroid use to include elevated intraocular pressure, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, alteration in glucose tolerance, elevation in blood pressure, behavioral and <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span> and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.</p>
<p>     </p>
<p>U.S. Patent No. 6,395,294</p>
<p>    </p>
<p>© 2007, 2008 Alcon, Inc.</p>
<p>    </p>
<p>ALCON LABORATORIES, INC.</p>
<p>Fort Worth, Texas 76134 USA</p>
<p><span class="Bold">9003982-0908</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="splSectionPDP"></a><a name="section-14"></a><p></p>
<h1>
PRINCIPAL DISPLAY PANEL
</h1>
<p class="First">NDC 0065-09543-01                Sterile</p>
<p>Triesence</p>
<p>(triamcinolone acetonide</p>
<p>Injectable suspension)</p>
<p>40 mg/mL</p>
<p>                                               1 mL</p>
<p>Preservative Free                Alcon<span class="Sup">®</span></p>
<div class="Figure"><img alt="
carton
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3f045347-3e5e-4bbd-90f8-6c3100985ca5&amp;name=carton.jpg"></div>
<div class="Figure"><img alt="
label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3f045347-3e5e-4bbd-90f8-6c3100985ca5&amp;name=label.jpg"></div>
<p>         </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRIESENCE 		
					</strong><br><span class="contentTableReg">triamcinolone acetonide injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0065-0543</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TRIAMCINOLONE ACETONIDE</strong> (TRIAMCINOLONE ACETONIDE) </td>
<td class="formItem">TRIAMCINOLONE ACETONIDE</td>
<td class="formItem">40 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM ACETATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0065-0543-01</td>
<td class="formItem">1 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022048</td>
<td class="formItem">10/01/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Alcon Laboratories, Inc.
							(008018525)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Alcon Laboratories, Inc. (008018525)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Alcon Laboratories, Inc.</td>
<td class="formItem"></td>
<td class="formItem">008018525</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a2412381-d9ed-4d7e-acb1-a97e730b12db</div>
<div>Set id: 3f045347-3e5e-4bbd-90f8-6c3100985ca5</div>
<div>Version: 6</div>
<div>Effective Time: 20110622</div>
</div>
</div> <div class="DistributorName">Alcon Laboratories, Inc.</div></p>
</body></html>
